Skip to main content

Peer Review reports

From: Axitinib as a third or further line of treatment in renal cancer: a single institution experience

Original Submission
12 Jan 2020 Submitted Original manuscript
15 Mar 2020 Reviewed Reviewer Report - Petros Grivas
15 Mar 2020 Reviewed Reviewer Report - NIKOLAOS GRIVAS
14 Apr 2020 Author responded Author comments - Giorgos Tsironis
Resubmission - Version 2
14 Apr 2020 Submitted Manuscript version 2
Publishing
21 Apr 2020 Editorially accepted
2 Jun 2020 Article published 10.1186/s12894-020-00618-1

You can find further information about peer review here.

Back to article page